Curocell

Curocell Operating Cash Flow

The Operating Cash Flow of Curocell (372320.KQ) as of Oct 27, 2026 is -29.99 B KRW. In the previous year, Operating Cash Flow was -28.42 B KRW — a change of 5.53% (lower).

Operating Cash Flow

-29.99 BKRW

YoY

5.53%

Last updated:

Operating Cash Flow of Curocell is 2025 -29.99 B KRW. Operating Cash Flow of Curocell was 2024 -28.42 B KRW. It decreases by 5.53% lower compared to the previous year.

The Curocell Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2021
-11.54 B KRW
Jan 1, 2022
-14.39 B KRW
Jan 1, 2023
-25.26 B KRW
Jan 1, 2024
-28.42 B KRW
Jan 1, 2025
-29.99 B KRW
The Curocell Operating Cash Flow history
YEAROperating Cash FlowYoY
-29.99 BKRW+5.53%
-28.42 BKRW+12.50%
-25.26 BKRW+75.54%
-14.39 BKRW+24.76%
-11.54 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Operating Cash Flow of Curocell is -29.99 B KRW in 2025.

Operating Cash Flow of Curocell changed from -28.42 B KRW to -29.99 B KRW, representing a 5.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Curocell since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curocell

All Key Metrics — Curocell